Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Amortizatization of Intangibles: 2020-2025

Historic Amortizatization of Intangibles for Legend Biotech (LEGN) over the last 4 years, with Jun 2025 value amounting to $100,000.

  • Legend Biotech's Amortizatization of Intangibles fell 72.68% to $100,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $908,000, marking a year-over-year decrease of 59.32%. This contributed to the annual value of $1.9 million for FY2024, which is 0.36% up from last year.
  • According to the latest figures from Q2 2025, Legend Biotech's Amortizatization of Intangibles is $100,000, which was down 21.88% from $128,000 recorded in Q1 2025.
  • Legend Biotech's Amortizatization of Intangibles' 5-year high stood at $885,000 during Q1 2024, with a 5-year trough of $100,000 in Q2 2025.
  • Over the past 3 years, Legend Biotech's median Amortizatization of Intangibles value was $366,000 (recorded in 2024), while the average stood at $408,300.
  • Per our database at Business Quant, Legend Biotech's Amortizatization of Intangibles soared by 1,451.85% in 2021 and then plummeted by 85.54% in 2025.
  • Legend Biotech's Amortizatization of Intangibles (Quarterly) stood at $419,000 in 2021, then spiked by 104.06% to $855,000 in 2022, then slumped by 43.63% to $482,000 in 2023, then fell by 24.07% to $366,000 in 2024, then slumped by 72.68% to $100,000 in 2025.
  • Its Amortizatization of Intangibles stands at $100,000 for Q2 2025, versus $128,000 for Q1 2025 and $366,000 for Q4 2024.